LSTA NASDAQ
Lisata Therapeutics, Inc.
1W: -1.9%
1M: -32.0%
3M: -6.4%
YTD: -48.0%
1Y: -56.6%
3Y: -51.7%
5Y: -94.3%
$1.02
-0.04 (-3.77%)
Weekly Expected Move ±10.9%
$1
$1
$1
$1
$1
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' -171.29.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
9 relationships9
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2022-04-27
Earliest Filing
2026-03-09
Latest Filing
acquirer: 3
partner: 3
target: 2
licensee: 1
Counterparties (Filed by LSTA)
9 relationshipsCompanies named in LSTA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Kuva Labs Inc. | — | acquirer | Parent company of Purchaser entering Agreement and Plan of Merger with Lisata Therapeutics | 2026-03-09 | View |
| Kuva Acquisition Corp. | — | acquirer | Wholly owned subsidiary of Kuva Labs Inc. entering Agreement and Plan of Merger with Lisata Therapeutics | 2026-03-09 | View |
| Kuva Labs Inc. | — | acquirer | Kuva Labs Inc. agreed to acquire Lisata Therapeutics, Inc. via a tender offer and subsequent merger. | 2026-02-27 | View |
| Catalent, Inc. | — | licensee | Lisata Therapeutics granted a non-exclusive license for its iRGD cyclic peptide technology to Catalent for use in its SM | 2025-10-08 | View |
| Kuva Labs, Inc. | — | partner | Entered into an exclusive license and collaboration agreement for certepetide development and commercialization | 2024-12-03 | View |
| Mi2 Holdings, LLC | — | partner | Parent company of Kuva Labs, Inc., the counterparty to the license and collaboration agreement | 2024-12-03 | View |
| Sanford Burnham Prebys Medical Discovery Institute | — | partner | Granted know-how and patents licensed to the Company which are now sublicensed to Kuva | 2024-12-03 | View |
| Cend Therapeutics, Inc. | — | target | Target company in the business combination merger with Lisata Therapeutics, Inc. | 2022-09-15 | View |
| Cend Therapeutics, Inc. | — | target | Target company in a merger agreement to be acquired by Caladrius Biosciences, Inc. | 2022-04-27 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-14 | Officer/Director Change; Exhibits | View | |
| 2026-09-17 | Material Agreement; Acquisition/Disposition; Unregistered Equity Sales; Officer/Director Change; Byl | Agreement Acquisition | View |
| 2026-08-04 | Exit/Disposal Costs; Officer/Director Change; Other Events; Exhibits | View | |
| 2026-07-24 | Termination of Agreement; Other Events | View | |
| 2026-07-17 | Material Agreement; Exhibits | Agreement | View |
| 2026-06-09 | Material Agreement; Exhibits | Agreement | View |
| 2026-06-01 | Other Events | View | |
| 2026-05-29 | Material Agreement; Exhibits | Agreement | View |
| 2026-05-04 | Material Agreement; Exhibits | Agreement | View |
| 2026-04-15 | Other Events | View | |
| 2026-04-03 | Other Events; Exhibits | View | |
| 2026-03-09 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2026-02-27 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2026-01-27 | Other Events | View | |
| 2026-01-21 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-11-06 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-10-14 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-10-08 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-08-07 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-07-15 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR